English
简体中文
Total: £ 56.28
Published Date: 2024-12-06 | Pages: 118 | Tables: 186 | Medical Care
The growth is attributed to the extensive research in the development of new therapies and the presence of robust pipeline drugs that are used to treat transthyretin.
The global market for Transthyretin Amyloidosis Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Transthyretin Amyloidosis Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Transthyretin Amyloidosis Treatment by region & country, by Type, and by Application.
The Transthyretin Amyloidosis Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Transthyretin Amyloidosis Treatment.
Market Segmentation
By Company
Pfizer Inc.
Johnson & Johnson Services, Inc.
Ionis Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
BridgeBio Pharma, Inc.
Bristol-Myers Squibb Company
Acrotech Biopharma
AstraZeneca
Astellas Pharma, Inc.
Prothena
SOM Biotech
Segment by Type:
ATTR-PN
ATTR-CM
Segment by Application
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Transthyretin Amyloidosis Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Transthyretin Amyloidosis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Transthyretin Amyloidosis Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Transthyretin Amyloidosis Treatment Product Introduction
1.2 Global Transthyretin Amyloidosis Treatment Market Size Forecast
1.3 Transthyretin Amyloidosis Treatment Market Trends & Drivers
1.3.1 Transthyretin Amyloidosis Treatment Industry Trends
1.3.2 Transthyretin Amyloidosis Treatment Market Drivers & Opportunity
1.3.3 Transthyretin Amyloidosis Treatment Market Challenges
1.3.4 Transthyretin Amyloidosis Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Transthyretin Amyloidosis Treatment Players Revenue Ranking (2023)
2.2 Global Transthyretin Amyloidosis Treatment Revenue by Company (2019-2024)
2.3 Key Companies Transthyretin Amyloidosis Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Transthyretin Amyloidosis Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Transthyretin Amyloidosis Treatment
2.6 Transthyretin Amyloidosis Treatment Market Competitive Analysis
2.6.1 Transthyretin Amyloidosis Treatment Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Transthyretin Amyloidosis Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transthyretin Amyloidosis Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 ATTR-PN
3.1.2 ATTR-CM
3.2 Global Transthyretin Amyloidosis Treatment Sales Value by Type
3.2.1 Global Transthyretin Amyloidosis Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Transthyretin Amyloidosis Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Transthyretin Amyloidosis Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital Pharmacies
4.1.2 Specialty Pharmacies
4.1.3 Retail Pharmacies
4.1.4 Online Pharmacies
4.2 Global Transthyretin Amyloidosis Treatment Sales Value by Application
4.2.1 Global Transthyretin Amyloidosis Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Transthyretin Amyloidosis Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Transthyretin Amyloidosis Treatment Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Transthyretin Amyloidosis Treatment Sales Value by Region
5.1.1 Global Transthyretin Amyloidosis Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Transthyretin Amyloidosis Treatment Sales Value by Region (2019-2024)
5.1.3 Global Transthyretin Amyloidosis Treatment Sales Value by Region (2025-2030)
5.1.4 Global Transthyretin Amyloidosis Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Transthyretin Amyloidosis Treatment Sales Value, 2019-2030
5.2.2 North America Transthyretin Amyloidosis Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Transthyretin Amyloidosis Treatment Sales Value, 2019-2030
5.3.2 Europe Transthyretin Amyloidosis Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Transthyretin Amyloidosis Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Transthyretin Amyloidosis Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Transthyretin Amyloidosis Treatment Sales Value, 2019-2030
5.5.2 South America Transthyretin Amyloidosis Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Transthyretin Amyloidosis Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Transthyretin Amyloidosis Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Transthyretin Amyloidosis Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Transthyretin Amyloidosis Treatment Sales Value
6.3 United States
6.3.1 United States Transthyretin Amyloidosis Treatment Sales Value, 2019-2030
6.3.2 United States Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Transthyretin Amyloidosis Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Transthyretin Amyloidosis Treatment Sales Value, 2019-2030
6.4.2 Europe Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Transthyretin Amyloidosis Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Transthyretin Amyloidosis Treatment Sales Value, 2019-2030
6.5.2 China Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Transthyretin Amyloidosis Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Transthyretin Amyloidosis Treatment Sales Value, 2019-2030
6.6.2 Japan Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Transthyretin Amyloidosis Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Transthyretin Amyloidosis Treatment Sales Value, 2019-2030
6.7.2 South Korea Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Transthyretin Amyloidosis Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Transthyretin Amyloidosis Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Transthyretin Amyloidosis Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Transthyretin Amyloidosis Treatment Sales Value, 2019-2030
6.9.2 India Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Transthyretin Amyloidosis Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Pfizer Inc.
7.1.1 Pfizer Inc. Profile
7.1.2 Pfizer Inc. Main Business
7.1.3 Pfizer Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions
7.1.4 Pfizer Inc. Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Pfizer Inc. Recent Developments
7.2 Johnson & Johnson Services, Inc.
7.2.1 Johnson & Johnson Services, Inc. Profile
7.2.2 Johnson & Johnson Services, Inc. Main Business
7.2.3 Johnson & Johnson Services, Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions
7.2.4 Johnson & Johnson Services, Inc. Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 Johnson & Johnson Services, Inc. Recent Developments
7.3 Ionis Pharmaceuticals, Inc.
7.3.1 Ionis Pharmaceuticals, Inc. Profile
7.3.2 Ionis Pharmaceuticals, Inc. Main Business
7.3.3 Ionis Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions
7.3.4 Ionis Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 Alnylam Pharmaceuticals, Inc. Recent Developments
7.4 Alnylam Pharmaceuticals, Inc.
7.4.1 Alnylam Pharmaceuticals, Inc. Profile
7.4.2 Alnylam Pharmaceuticals, Inc. Main Business
7.4.3 Alnylam Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions
7.4.4 Alnylam Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 Alnylam Pharmaceuticals, Inc. Recent Developments
7.5 BridgeBio Pharma, Inc.
7.5.1 BridgeBio Pharma, Inc. Profile
7.5.2 BridgeBio Pharma, Inc. Main Business
7.5.3 BridgeBio Pharma, Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions
7.5.4 BridgeBio Pharma, Inc. Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 BridgeBio Pharma, Inc. Recent Developments
7.6 Bristol-Myers Squibb Company
7.6.1 Bristol-Myers Squibb Company Profile
7.6.2 Bristol-Myers Squibb Company Main Business
7.6.3 Bristol-Myers Squibb Company Transthyretin Amyloidosis Treatment Products, Services and Solutions
7.6.4 Bristol-Myers Squibb Company Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Bristol-Myers Squibb Company Recent Developments
7.7 Acrotech Biopharma
7.7.1 Acrotech Biopharma Profile
7.7.2 Acrotech Biopharma Main Business
7.7.3 Acrotech Biopharma Transthyretin Amyloidosis Treatment Products, Services and Solutions
7.7.4 Acrotech Biopharma Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 Acrotech Biopharma Recent Developments
7.8 AstraZeneca
7.8.1 AstraZeneca Profile
7.8.2 AstraZeneca Main Business
7.8.3 AstraZeneca Transthyretin Amyloidosis Treatment Products, Services and Solutions
7.8.4 AstraZeneca Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)
7.8.5 AstraZeneca Recent Developments
7.9 Astellas Pharma, Inc.
7.9.1 Astellas Pharma, Inc. Profile
7.9.2 Astellas Pharma, Inc. Main Business
7.9.3 Astellas Pharma, Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions
7.9.4 Astellas Pharma, Inc. Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)
7.9.5 Astellas Pharma, Inc. Recent Developments
7.10 Prothena
7.10.1 Prothena Profile
7.10.2 Prothena Main Business
7.10.3 Prothena Transthyretin Amyloidosis Treatment Products, Services and Solutions
7.10.4 Prothena Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)
7.10.5 Prothena Recent Developments
7.11 SOM Biotech
7.11.1 SOM Biotech Profile
7.11.2 SOM Biotech Main Business
7.11.3 SOM Biotech Transthyretin Amyloidosis Treatment Products, Services and Solutions
7.11.4 SOM Biotech Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)
7.11.5 SOM Biotech Recent Developments
8 Industry Chain Analysis
8.1 Transthyretin Amyloidosis Treatment Industrial Chain
8.2 Transthyretin Amyloidosis Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Transthyretin Amyloidosis Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Transthyretin Amyloidosis Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Transthyretin Amyloidosis Treatment Market Trends
Table 2. Transthyretin Amyloidosis Treatment Market Drivers & Opportunity
Table 3. Transthyretin Amyloidosis Treatment Market Challenges
Table 4. Transthyretin Amyloidosis Treatment Market Restraints
Table 5. Global Transthyretin Amyloidosis Treatment Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Transthyretin Amyloidosis Treatment Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Transthyretin Amyloidosis Treatment Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Transthyretin Amyloidosis Treatment Product Type
Table 9. Key Companies Time to Begin Mass Production of Transthyretin Amyloidosis Treatment
Table 10. Global Transthyretin Amyloidosis Treatment Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transthyretin Amyloidosis Treatment as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Transthyretin Amyloidosis Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Transthyretin Amyloidosis Treatment Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Transthyretin Amyloidosis Treatment Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Transthyretin Amyloidosis Treatment Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Transthyretin Amyloidosis Treatment Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Transthyretin Amyloidosis Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Transthyretin Amyloidosis Treatment Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Transthyretin Amyloidosis Treatment Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Transthyretin Amyloidosis Treatment Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Transthyretin Amyloidosis Treatment Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Transthyretin Amyloidosis Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Transthyretin Amyloidosis Treatment Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Transthyretin Amyloidosis Treatment Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Transthyretin Amyloidosis Treatment Sales Value by Region (2019-2024) & (%)
Table 27. Global Transthyretin Amyloidosis Treatment Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Transthyretin Amyloidosis Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Transthyretin Amyloidosis Treatment Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Transthyretin Amyloidosis Treatment Sales Value, (2025-2030) & (US$ Million)
Table 31. Pfizer Inc. Basic Information List
Table 32. Pfizer Inc. Description and Business Overview
Table 33. Pfizer Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions
Table 34. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of Pfizer Inc. (2019-2024)
Table 35. Pfizer Inc. Recent Developments
Table 36. Johnson & Johnson Services, Inc. Basic Information List
Table 37. Johnson & Johnson Services, Inc. Description and Business Overview
Table 38. Johnson & Johnson Services, Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions
Table 39. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of Johnson & Johnson Services, Inc. (2019-2024)
Table 40. Johnson & Johnson Services, Inc. Recent Developments
Table 41. Ionis Pharmaceuticals, Inc. Basic Information List
Table 42. Ionis Pharmaceuticals, Inc. Description and Business Overview
Table 43. Ionis Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions
Table 44. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of Ionis Pharmaceuticals, Inc. (2019-2024)
Table 45. Ionis Pharmaceuticals, Inc. Recent Developments
Table 46. Alnylam Pharmaceuticals, Inc. Basic Information List
Table 47. Alnylam Pharmaceuticals, Inc. Description and Business Overview
Table 48. Alnylam Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions
Table 49. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of Alnylam Pharmaceuticals, Inc. (2019-2024)
Table 50. Alnylam Pharmaceuticals, Inc. Recent Developments
Table 51. BridgeBio Pharma, Inc. Basic Information List
Table 52. BridgeBio Pharma, Inc. Description and Business Overview
Table 53. BridgeBio Pharma, Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions
Table 54. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of BridgeBio Pharma, Inc. (2019-2024)
Table 55. BridgeBio Pharma, Inc. Recent Developments
Table 56. Bristol-Myers Squibb Company Basic Information List
Table 57. Bristol-Myers Squibb Company Description and Business Overview
Table 58. Bristol-Myers Squibb Company Transthyretin Amyloidosis Treatment Products, Services and Solutions
Table 59. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of Bristol-Myers Squibb Company (2019-2024)
Table 60. Bristol-Myers Squibb Company Recent Developments
Table 61. Acrotech Biopharma Basic Information List
Table 62. Acrotech Biopharma Description and Business Overview
Table 63. Acrotech Biopharma Transthyretin Amyloidosis Treatment Products, Services and Solutions
Table 64. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of Acrotech Biopharma (2019-2024)
Table 65. Acrotech Biopharma Recent Developments
Table 66. AstraZeneca Basic Information List
Table 67. AstraZeneca Description and Business Overview
Table 68. AstraZeneca Transthyretin Amyloidosis Treatment Products, Services and Solutions
Table 69. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of AstraZeneca (2019-2024)
Table 70. AstraZeneca Recent Developments
Table 71. Astellas Pharma, Inc. Basic Information List
Table 72. Astellas Pharma, Inc. Description and Business Overview
Table 73. Astellas Pharma, Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions
Table 74. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of Astellas Pharma, Inc. (2019-2024)
Table 75. Astellas Pharma, Inc. Recent Developments
Table 76. Prothena Basic Information List
Table 77. Prothena Description and Business Overview
Table 78. Prothena Transthyretin Amyloidosis Treatment Products, Services and Solutions
Table 79. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of Prothena (2019-2024)
Table 80. Prothena Recent Developments
Table 81. SOM Biotech Basic Information List
Table 82. SOM Biotech Description and Business Overview
Table 83. SOM Biotech Transthyretin Amyloidosis Treatment Products, Services and Solutions
Table 84. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of SOM Biotech (2019-2024)
Table 85. SOM Biotech Recent Developments
Table 86. Key Raw Materials Lists
Table 87. Raw Materials Key Suppliers Lists
Table 88. Transthyretin Amyloidosis Treatment Downstream Customers
Table 89. Transthyretin Amyloidosis Treatment Distributors List
Table 90. Research Programs/Design for This Report
Table 91. Key Data Information from Secondary Sources
Table 92. Key Data Information from Primary Sources
Table 93. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Transthyretin Amyloidosis Treatment Product Picture
Figure 2. Global Transthyretin Amyloidosis Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Transthyretin Amyloidosis Treatment Sales Value (2019-2030) & (US$ Million)
Figure 4. Transthyretin Amyloidosis Treatment Report Years Considered
Figure 5. Global Transthyretin Amyloidosis Treatment Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Transthyretin Amyloidosis Treatment Revenue in 2023
Figure 7. Transthyretin Amyloidosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. ATTR-PN Picture
Figure 9. ATTR-CM Picture
Figure 10. Global Transthyretin Amyloidosis Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 11. Global Transthyretin Amyloidosis Treatment Sales Value Market Share by Type, 2023 & 2030
Figure 12. Product Picture of Hospital Pharmacies
Figure 13. Product Picture of Specialty Pharmacies
Figure 14. Product Picture of Retail Pharmacies
Figure 15. Product Picture of Online Pharmacies
Figure 16. Global Transthyretin Amyloidosis Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 17. Global Transthyretin Amyloidosis Treatment Sales Value Market Share by Application, 2023 & 2030
Figure 18. North America Transthyretin Amyloidosis Treatment Sales Value (2019-2030) & (US$ Million)
Figure 19. North America Transthyretin Amyloidosis Treatment Sales Value by Country (%), 2023 VS 2030
Figure 20. Europe Transthyretin Amyloidosis Treatment Sales Value (2019-2030) & (US$ Million)
Figure 21. Europe Transthyretin Amyloidosis Treatment Sales Value by Country (%), 2023 VS 2030
Figure 22. Asia Pacific Transthyretin Amyloidosis Treatment Sales Value (2019-2030) & (US$ Million)
Figure 23. Asia Pacific Transthyretin Amyloidosis Treatment Sales Value by Country (%), 2023 VS 2030
Figure 24. South America Transthyretin Amyloidosis Treatment Sales Value (2019-2030) & (US$ Million)
Figure 25. South America Transthyretin Amyloidosis Treatment Sales Value by Country (%), 2023 VS 2030
Figure 26. Middle East & Africa Transthyretin Amyloidosis Treatment Sales Value (2019-2030) & (US$ Million)
Figure 27. Middle East & Africa Transthyretin Amyloidosis Treatment Sales Value by Country (%), 2023 VS 2030
Figure 28. Key Countries/Regions Transthyretin Amyloidosis Treatment Sales Value (%), (2019-2030)
Figure 29. United States Transthyretin Amyloidosis Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 30. United States Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030
Figure 31. United States Transthyretin Amyloidosis Treatment Sales Value by Application (%), 2023 VS 2030
Figure 32. Europe Transthyretin Amyloidosis Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 33. Europe Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030
Figure 34. Europe Transthyretin Amyloidosis Treatment Sales Value by Application (%), 2023 VS 2030
Figure 35. China Transthyretin Amyloidosis Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 36. China Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030
Figure 37. China Transthyretin Amyloidosis Treatment Sales Value by Application (%), 2023 VS 2030
Figure 38. Japan Transthyretin Amyloidosis Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 39. Japan Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030
Figure 40. Japan Transthyretin Amyloidosis Treatment Sales Value by Application (%), 2023 VS 2030
Figure 41. South Korea Transthyretin Amyloidosis Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 42. South Korea Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030
Figure 43. South Korea Transthyretin Amyloidosis Treatment Sales Value by Application (%), 2023 VS 2030
Figure 44. Southeast Asia Transthyretin Amyloidosis Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 45. Southeast Asia Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030
Figure 46. Southeast Asia Transthyretin Amyloidosis Treatment Sales Value by Application (%), 2023 VS 2030
Figure 47. India Transthyretin Amyloidosis Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 48. India Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030
Figure 49. India Transthyretin Amyloidosis Treatment Sales Value by Application (%), 2023 VS 2030
Figure 50. Transthyretin Amyloidosis Treatment Industrial Chain
Figure 51. Transthyretin Amyloidosis Treatment Manufacturing Cost Structure
Figure 52. Channels of Distribution (Direct Sales, and Distribution)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
